UK Markets open in 7 hrs 6 mins

Johnson & Johnson (JNJ)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
161.30+1.19 (+0.74%)
At close: 4:00PM EDT
161.75 +0.45 (+0.28%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close160.11
Open161.03
Bid161.45 x 800
Ask161.49 x 1300
Day's range160.44 - 161.81
52-week range133.65 - 179.92
Volume6,918,407
Avg. volume5,908,775
Market cap424.767B
Beta (5Y monthly)0.70
PE ratio (TTM)28.49
EPS (TTM)5.66
Earnings date19 Oct 2021
Forward dividend & yield4.24 (2.56%)
Ex-dividend date23 Aug 2021
1y target est187.17
  • Motley Fool

    Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?

    Johnson & Johnson (NYSE: JNJ) recently announced positive results from a phase 2 study of its RSV vaccine candidate. In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) to top.

  • Motley Fool

    3 Dividend Stocks to Buy If the Stock Market Crashes

    Most stocks sink when the stock market itself plunges. Not only are their stocks available at a discount, but the lower share prices also allow you to lock in higher dividend yields. No one knows for sure whether the stock market will crash anytime soon.

  • Motley Fool

    Will Johnson & Johnson Win Authorization for Its COVID-19 Booster?

    A U.S. Food and Drug Administration (FDA) advisory committee has reviewed Johnson & Johnson's (NYSE: JNJ) data supporting boosters of its COVID-19 vaccine. The FDA gets the final say in the matter, though. In this Motley Fool Live video recorded on Oct. 6, Motley Fool contributors Keith Speights and Brian Orelli discuss J&J's prospects for authorization of boosters.